Human blessing is attacking innovative drugs!

Recently, Renfu Medicine, the leading pharmaceutical company in anesthesia and sedation, once again sold huge assets to arouse industry attention.
The company plans to transfer its shares of Huatai Insurance to Anda North America for 1.
026 billion yuan
.
Since the implementation of “Reverting Focus” in 2017, Renfu Medicine has become the norm.
The company has increased its R&D investment after returning funds.
Class 1 new drugs and first generic drugs have gradually entered the harvest period in recent years.
The company’s pharmaceuticals The proportion of manufacturing revenue will also rise to 50% in 2020
.
"Slimming" successful people, what other hot models are ready to go? The proportion of pharmaceutical manufacturing has risen to 50%, with R&D investment reaching 1 billion.
Renfu Medicine is a comprehensive pharmaceutical industry group.
In addition to its main pharmaceutical business, it is also engaged in reproductive health, environmental protection, real estate, finance and other fields
.
In 2017, the company clearly implemented the strategy of “refocusing and focusing”.
On the one hand, it focused resources on the development of established professional subdivisions to achieve business focus, and on the other hand, it carried out the divestiture of non-core businesses and assets to optimize the capital structure
.
Figure 1: Changes in the revenue share of Renfu Medicine’s various business segments in recent years.
Source: Company’s annual report According to annual report data, pharmaceutical manufacturing, pharmaceutical wholesale and related businesses have always been Renfu Medicine’s two major operating segments.
But the gross profit margin is very different
.
The gross profit margin of the company's pharmaceutical manufacturing industry will remain above 65% from 2017 to 2020, while the gross profit margin of pharmaceutical wholesale and related businesses will be less than 20%.
Focusing on the pharmaceutical manufacturing industry, it is imminent to increase the company's overall gross profit margin
.
In 2016, the company's overall gross profit margin was 36.
79%.
After experiencing labor pains, the company's pharmaceutical manufacturing revenue accounted for 50% in 2020, and the company's overall gross profit margin also rose to 42.
41%.
The "refocusing" strategy has achieved remarkable results.

.
Figure 2: The changes in R&D investment in Renfu Medicine in recent years.
Source: The company's annual report.
Workers must first sharpen their tools.
In order to enrich product reserves and cultivate long-term competitiveness, Renfu Medicine insists on independent R&D and innovation.
In recent years The company continues to increase its R&D investment.
In 2018, the R&D investment exceeded 700 million yuan, accounting for 4% of the company's total revenue, and in 2020 it reached 937 million yuan, accounting for 4.
6% of the company's total revenue
.
In 2021, the company got rid of the epidemic situation, and achieved positive growth in revenue and net profit in the first three quarters, and R&D investment is also expected to reach 1 billion yuan
.
Renfu Medicine has also increased its shareholding ratio in Yichang Renfu, a key subsidiary.
In October 2020, Renfu Medicine will increase its shareholding in Yichang Renfu to 80% for a total consideration of 2.
4 billion yuan.
In the Yidingzhuang plan, part of the raised funds will be used for the construction of the Yichang People's Welfare project, further focusing on the narcotic drugs business and consolidating its leading position
.
fruitful! 2 Class 1 new drugs and 4 first imitations have successfully broken through.
Table 1: The status of Renfu Medicine's products approved for marketing since 2017.
Source: Meinenet MED2.
0 China Drug Evaluation Database Continuous R&D investment has brought the company Rich fruits
.
From 2017 to the present, Renfu Medicine has approved 16 new products, 2 new drugs of category 1, 3 first imitations + the first over-reviewed product focused on the field of neurological drugs, and 1 first imitation + first over-reviewed product is cardiovascular System drugs
.
Renfu Medicine’s remazolam besylate for injection was reported for production in 2018 and was subsequently included in the priority review.
It was officially approved in 2020.
It is the company’s first class 1 new chemical drug and has also become Hengrui Medicine’s The strongest competitor of Class 1 new drug remazolam tosylate for injection; the company's second Class 1 new drug, propofol disodium for injection is also reported for production in 2018, approved for listing in 2021, and 3 billion propofol market It is expected to usher in a major reshuffle
.
Midazolam oral solution was reported for production in 2019, and it was included in the priority review and approved in 2021.
It is the first oral solution for sedation in children before surgery or diagnosis in China; the narcotic analgesic Alfen Hydrochloride/Tai/ Nissan injection was approved in 2020, marking that Renfu Medicine has officially become a domestic pharmaceutical company with a full range of fen/tai/ni products; Bupropion Hydrochloride Sustained-Release Tablets (II) are the Sino-US joint line of Renfu Medicine These 3 new products were reported for production and approved according to the new classification, becoming the first domestic imitation + first over-reviewed enterprise
.
In the field of neurological drugs, the company has also been approved for bupropion hydrochloride sustained-release tablets and levobupivacaine hydrochloride injection, and Renfu Medicine has won the first review
.
In addition, the company has also been approved for new products in the fields of digestive system and metabolic drugs, cardiovascular system drugs, genitourinary system and sex hormone drugs, and dermatological drugs
.
Among them, the subsidiary Henan Bainian Kangxin Pharmaceutical's propranolol hydrochloride oral solution is the first domestic imitation + the first review, metformin hydrochloride sustained-release tablets and potassium chloride sustained-release tablets are Sino-US collinear products, and metoprolol tartrate Er injection submitted its consistency evaluation and was approved in 2020, and won the first review of the product
.
Table 2: New drugs declared by Renfu Medicine since 2017 (excluding new indications) Source: Meinenet MED2.
0 Chinese Drug Evaluation Database Renfu Medicine's new drugs under development are also very eye-catching, the company's first proprietary Chinese medicine 1 The new class of drug, Desmodium Styraci total flavonoids capsules, is reporting for production, which is expected to become the company's new breakthrough in the field of traditional Chinese medicine for urinary system diseases
.
Three new class 1 chemical drugs HW021199 tablets, RF-A089 capsules and morphine-6-glucuronide injection are already in the phase I clinical stage
.
In terms of improved new drugs, paracetamol/hydrocodone sustained-release tablets, sufen/tai/ni transdermal patches and dexmedetomidine transdermal patches are all suitable for analgesia, and currently sufen/tai/ni transdermal patches Phase I clinical is ongoing
.
Table 3: The generic drugs that Renfu Medicine has reported for production and are under review since 2017.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database.
In terms of generic drugs, Renfu Medicine currently has 3 products under review that are expected to hit the country's first imitation
.
Shugeng Sodium Gluconate Injection has applied for imitation and listing of 20 companies, and the competition for the first imitation is fierce; the first imitation of oxycodone hydrochloride sustained-release tablets will be decided between Renfu Pharmaceutical and Hefei Lifang Pharmaceutical; potassium chloride slow Release tablets (Ⅰ) Currently, only Renfu Pharmaceutical has applied for production, and there is a high probability that it can win the first copy
.
Renfu Medicine also conducted a comprehensive review of its product line in 2019, and concentrated resources on the development of core areas such as anesthetics, other nervous system drugs, gender health drugs, Uyghur national drugs, skin external drugs, and respiratory system drugs.
It is expected that the company will be in the above-mentioned There will be more and more new products in the field
.
Renfu Medicine "sells a new future", and these shares are to be sold in 2022.
"Refocusing" is the most important task of Renfu Medicine in recent years.
The company is determined to withdraw from sub-sectors where the competitive advantage is not obvious or the synergy is weak.
, Concentrate resources to build a core product line, and form a development pattern that is dominated by the pharmaceutical industry and supplemented by pharmaceutical commerce
.
Table 4: Some large-scale asset sales of Renfu Medicine since 2017 Source: Company annual report, semi-annual report, announcement According to the company's annual report data, Renfu Medicine has successively sold medical services, gender health and other business-related assets since 2017, accumulatively The total investment income, assets, and equity transfer payments totaled more than 6 billion yuan
.
Judging from the company's new product output in the pharmaceutical manufacturing sector in recent years, the withdrawal of funds will play an extremely important role in the company's future development
.
It is reported that Renfu Medicine will continue to promote the equity transfer of Zhengzhou Renfubosai Biotechnology, Wuhan Haoyijia Technology and other companies.
It is expected that the above-mentioned projects are expected to land after 2022
.
In the past few years, under the wave of aging, many pharmaceutical companies have begun to "addition" and actively deploy the big health sector.
In the past two years, medical aesthetics has become a new trend, and listed pharmaceutical companies such as East China Pharmaceutical and Sihuan Pharmaceutical have increased their product introduction.
However, Renfu Medicine "does subtraction" at this time
.
Some people in the industry believe that the sale of assets by pharmaceutical companies is shifting from diversification to the main business.
The divestiture of weak businesses is conducive to focusing on strong businesses.
It can not only meet the needs of the company's strategic transformation in the current operating environment, but also help pharmaceutical companies to further their efforts.
Invigorate assets, optimize resource allocation, and control operating risks
.
Especially with the continuous advancement of the domestic medical reform, leading pharmaceutical companies that "do specialized, refined, and stronger" have more market voices
.
The main force of Renfu Medicine is in the "fine hemp" market, which has strong professionalism and high industry barriers.
Compared with the price cuts brought by mass purchases, fine hemp drugs are controlled by the state and have greater profitability.
Strong stability
.
In recent years, domestic pharmaceutical companies have made remarkable achievements in innovation.
As the leading echelon, Renfu Medicine has also successively won two new chemical drugs of category 1 and the company’s first Chinese patent medicine of category 1 new drugs will soon be available, which is expected to further consolidate its leading position.
After "slimming", Renfu Medicine may usher in a more glorious era
.
Source: Meinnet database, announcements of listed companies, etc.
Note: Statistics are as of November 25.
If there are any omissions, please correct me!